Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • NHS Psychological Support
    • Confidential Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Subscribe to Search results

Dr Bell, Consultant Gastroenterologist at Ipswich Hospital, sought advice from the CMO regarding funding for interferon treatment. He reported that the District Health Authority had described the funding for the treatment as a "grey area".

Published on: 20 September, 2024

The West Midlands Director of Public Health wrote to the Deputy CMO to say that about 300 patients infected through transfusions were expected to be identified through the Hepatitis C lookback, with potential treatment costs of £500,000, and asked "who is going to pay."

Published on: 10 October, 2024

The Deputy CMO stated that "patients on interferon require frequent monitoring of their blood count and biochemistry. For these reasons therefore it would be usual for hospitals rather than GPs, to prescribe Interferon. If they decide that this is what [is] required clinically, then the patient's Health Authority [or] GP fundholder, as purchasers, will then have to consider whether or not to fund the treatment having regard to their priorities."

Published on: 20 September, 2024

Graham Barker of the Haemophilia Society wrote to the Department of Health to say that "the Society believes that the provision of interferon alpha for the treatment of HCV should be centrally funded."

Published on: 20 September, 2024

At a meeting of regional haemophilia centre directors Dr Brian Colvin said he "knew of problems in funding interferon and he thought that the Department of Health should confirm that this treatment would be funded when recommended by a physician."

Published on: 08 October, 2024

The British Liver Trust, Haemophilia Society and Mainliners sent a letter to the Secretary of State, Stephen Dorrell, saying they were particularly concerned that significant numbers of people infected with Hepatitis C, were not getting access to "treatment with Interferon or other drugs".

Published on: 20 September, 2024

The haemophilia centre directors met. Dr Frank Hill reported that it was "an on-going battle to persuade purchasers to pay for [interferon treatment]." It was proposed at the meeting by Dr Brian Colvin that Dr Andrzej Rejman, a senior medical officer at the Department of Health, be contacted if haemophilia centre directors encountered difficulties.

Published on: 20 September, 2024

Graham Barker of the Haemophilia Society continued to highlight instances of interferon treatment being denied on the grounds of cost.

Published on: 20 September, 2024

The Department of Health replied to Graham Baker, to say that it did not hold back money centrally or allocate resources to support specific treatments for particular segments of the population and that purchasers in local authorities were responsible for assessing the health needs of local residents.

Published on: 20 September, 2024

Professor Howard Thomas wrote to the Department of Health to report difficulties of funding for interferon treatment.

Published on: 20 September, 2024

The Department of Health replied to Professor Howard Thomas maintaining the policy line that purchasers in local authorities were responsible for assessing the health needs of local residents.

Published on: 20 September, 2024

Dr Hugh Nicholas, a senior medical officer in the Department of Health, expressed concern that the allocation of resources for the treatment of Hepatitis C may be "very patchy" across the country.

Published on: 20 September, 2024

The Department of Health wrote to the Haemophilia Society that the cases it, and the UKHCDO, had raised had been investigated, and the relevant health authorities and trusts had reported to it that interferon had now been provided.

Published on: 20 September, 2024

The British Liver Trust released a press release noting that treatment, counselling and support services for Hepatitis C were inadequate according to a survey of liver units.

Published on: 20 September, 2024

The Department of Health responded to the British Liver Trust stating that "The majority of patients who will have been at risk of exposure to hepatitis C have been tested for Hepatitis C and following further investigation are being treated with alpha interferon where it is considered clinically appropriate."

Published on: 20 September, 2024

It was noted there was a tension between the need for a central initiative to deal with Hepatitis C and the aim of leaving the NHS to determine its own priorities based on assessment of local needs and there was a need to confirm whether to maintain the line in response to requests for departmental action on additional resources.

Published on: 20 September, 2024

Dr Metters was told that the commitment given was to provide treatment for Hepatitis C where appropriate or necessary and that there had been no firm commitment to provide treatment in every case.

Published on: 20 September, 2024

Document showing extracts from debates and questions about the lookback exercise and haemophilia and Hepatitis C.

Published on: 20 September, 2024

There was a ministerial commitment "to investigate allegations of problems of access to alpha interferon."

Published on: 20 September, 2024

A paper on Hepatitis C was prepared for a meeting of the NHS Executive stated: "The cost of treatment with alpha interferon (£2-5,000/patient) is already placing a considerable burden on purchasers and the pressure to prescribe Alpha Interferon widely is growing."

Published on: 10 October, 2024

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 2350
  • Page 2351
  • Page 2352
  • Page 2353
  • Current page 2354
  • Page 2355
  • Page 2356
  • Page 2357
  • Page 2358
  • …
  • Next page Next
  • Last page Last

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.